RxDoctor Payments Data

Maher Abdulla, MD

Internal Medicine · Warner Robins, GANPI 1316997489

Payments from drug & device makers

$9,586in general payments, 2019–2025

Across 559 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Bayer$852
  • AstraZeneca$746
  • Amgen$648
  • AbbVie$593
  • Otsuka America Pharmaceutical, Inc.$498
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,48899%
  • Education$390%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk86$1,274
Bayer40$852
AstraZeneca45$746
Amgen(2 entities)38$648
AbbVie(2 entities)32$593
Otsuka America Pharmaceutical, Inc.25$498
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$458
Lilly USA, LLC25$431
Astellas Pharma US Inc19$410
Neos Therapeutics, LP21$357
GSK23$336
Novartis12$235
Mylan Specialty L.p.13$223
Pfizer11$208
Axsome Therapeutics, Inc.10$188
Johnson & Johnson9$166
Supernus Pharmaceuticals, Inc.16$159
Upsher-smith Laboratories LLC8$126
Lundbeck LLC6$119
Sanofi-aventis U.S. LLC7$115
Eisai Inc.5$103
Abbott5$90
Boehringer Ingelheim6$88
Kowa Pharmaceuticals America, Inc.6$86
Teva Pharmaceuticals USA, Inc.6$80
Biogen3$69
Mannkind Corporation1$59
Biohaven Pharmaceuticals, Inc.4$59
Sunovion Pharmaceuticals Inc.4$51
Abiomed2$50
Noven Therapeutics, LLC2$45
Biohaven Pharmaceutical Holding Company Ltd.3$45
Sumitomo Pharma America, Inc.2$43
Antares Pharma, Inc.2$39
Arbor Pharmaceuticals, Inc.3$38
Aytu Biopharma, Inc.3$37
Daiichi Sankyo Inc.2$36
E.r. Squibb & Sons, L.L.C.2$29
Adlon Therapeutics L.p.2$28
Baxter Healthcare1$27
Viatris Specialty LLC1$26
Intra-sana Laboratories2$25
Xeris Pharmaceuticals, Inc.1$20
Shield Therapeutics Inc1$20
Ironshore Pharmaceuticals Inc.1$19
Almatica Pharma LLC1$18
Impel Pharmaceuticals Inc.1$18
Exact Sciences1$17
Smith+Nephew1$17
Tolmar, Inc.1$16
Esperion Therapeutics, Inc.1$16
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$16
Currax Pharmaceuticals LLC1$15
Genentech USA, Inc.1$14
Dexcom, Inc.1$13
Senseonics, Incorporated1$13
Jazz Pharmaceuticals Inc.1$13
Medtronic1$12
Global Blood Therapeutics, Inc.1$12
Shionogi Inc1$12

How this compares

$9,586 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$364,368
Medicare patients
525
Services billed
5,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide374$474,242
MounjaroTirzepatide328$454,770
EliquisApixaban214$214,211
Xigduo XrDapaglifloz Propaned/Metformin112$114,547
Xeljanz XrTofacitinib Citrate18$104,077
FarxigaDapagliflozin Propanediol128$103,104
Humira(Cf) PenAdalimumab12$96,695
JardianceEmpagliflozin76$79,911
OtezlaApremilast20$74,447
Synjardy XrEmpagliflozin/Metformin Hcl65$63,301
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$53,612
EntrestoSacubitril/Valsartan84$53,298
XareltoRivaroxaban57$44,132
Trijardy XrEmpaglifloz/Linaglip/Metformin27$31,699
KerendiaFinerenone35$29,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$1,274$510,388399 claims
Lilly USA, LLCMounjaro$431$454,770328 claims
PfizerEliquis$208$214,211214 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$88$174,911168 claims
AstraZenecaFarxiga, Breztri Aerosphere$746$117,768151 claims
AmgenOtezla$648$74,44720 claims
GSKTrelegy Ellipta$336$53,61258 claims
NovartisEntresto$235$53,29884 claims
Johnson & JohnsonXarelto$166$44,13257 claims
BayerKerendia$852$29,77335 claims
Astellas Pharma US IncMyrbetriq$410$12,66717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →